These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23876389)

  • 1. Call to action for dengue vaccine failure.
    Mahalingam S; Herring BL; Halstead SB
    Emerg Infect Dis; 2013 Aug; 19(8):1335-7. PubMed ID: 23876389
    [No Abstract]   [Full Text] [Related]  

  • 2. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection.
    Martinez DR; Metz SW; Baric RS
    Cell Host Microbe; 2021 Jan; 29(1):13-22. PubMed ID: 33444553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for a dengue virus vaccine.
    Whitehead SS; Blaney JE; Durbin AP; Murphy BR
    Nat Rev Microbiol; 2007 Jul; 5(7):518-28. PubMed ID: 17558424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current progress in dengue vaccines.
    Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
    J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
    Yang Y; Meng Y; Halloran ME; Longini IM
    Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live attenuated vaccine: the first clinically approved dengue vaccine?
    Fink K; Shi PY
    Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the role of a recently licensed dengue vaccine in Australian travellers.
    Thevarajan I; Torresi J; Simmons C
    Med J Aust; 2020 Feb; 212(3):102-103.e1. PubMed ID: 31909484
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-dengue Vaccines: From Development to Clinical Trials.
    Pinheiro-Michelsen JR; Souza RDSO; Santana IVR; da Silva PS; Mendez EC; Luiz WB; Amorim JH
    Front Immunol; 2020; 11():1252. PubMed ID: 32655561
    [No Abstract]   [Full Text] [Related]  

  • 13. DENGUE VACCINES.
    Thisyakorn U; Thisyakorn C
    Southeast Asian J Trop Med Public Health; 2015; 46 Suppl 1():138-45. PubMed ID: 26506740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
    Pitisuttithum P; Bouckenooghe A
    Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D; Andrade P; Nascimento EJM; Parker A; Narvekar P; Dean HJ; Harris E
    J Infect Dis; 2021 Feb; 223(2):247-257. PubMed ID: 32572472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CD4
    Angelo MA; Grifoni A; O'Rourke PH; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
    J Virol; 2017 Mar; 91(5):. PubMed ID: 27974563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue vaccine prospects: a step forward.
    Guy B; Almond J; Lang J
    Lancet; 2011 Jan; 377(9763):381-2. PubMed ID: 21277439
    [No Abstract]   [Full Text] [Related]  

  • 19. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
    Galula JU; Salem GM; Chang GJ; Chao DY
    Hum Vaccin Immunother; 2019; 15(10):2328-2336. PubMed ID: 31314657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.